Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain drugs.
Its fellow German pharma company Stada is looking to acquire a portfolio of Grunenthal’s branded drugs that would include the pain treatments Tramadol, Zaldiar and Transtec.
Also on the table is Palexia, Grunenthal’s novel first-in-class painkiller, which is expected to make annual sales of up to 25 million euros, but this has not yet been factored into the deal price.
